Building the Premier Women’s Health Company

June 2020

TherapeuticsMD®
For Her. For Life.
Forward-Looking Statements

This presentation by TherapeuticsMD, Inc. (referred to as “we,” “our,” or “the Company”) may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of our managerial experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate.

Forward-looking statements in this presentation are made as of the date of this presentation, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which may be outside of our control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the Securities and Exchange Commission (SEC), including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as our current reports on Form 8-K, and include the following: the company’s ability to protect the intellectual property related to its products; the effects of the COVID-19 pandemic; the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA®, BIJUVA® and its hormone therapy drug candidates and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility, including the conditions to draw an additional tranche thereunder and whether the lender will make such tranche available; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; whether the FDA will approve the efficacy supplement for the lower dose of BIJUVA; the company’s ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to commercialize and distribute the company’s products; the ability of the company’s marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. This non-promotional presentation is intended for investor audiences only.
COVID-19 Strategic Overview

Our approach is strategic, highly focused and achievable:

- Now that we have patient, provider and net revenue data on all 3 of our products, we have developed a path to reduce overall expenses and reallocate our resources that maintains our goal of achieving EBITDA breakeven in 2021.

- We believe we are positioned to capitalize on emerging market trends that have been accelerated by COVID-19 with our retail and online distribution channels.

- In the short-term, we have adjusted our strategy to be primarily focused on ANNOVERA and IMVEXXY.
Portfolio Strategic Focus

- ANNOVERA will remain our primary focus because of the positive market reception and net revenue per unit results that are a full year ahead of our internal expectations.

- IMVEXXY is our second priority as it has gained traction amongst the prescribing population and is now the fastest growing product in the category.

- To fund these initiatives, we are pausing the majority of our BIJUVA related promotional activities.

- We have been able to cut costs considerably by pausing BIJUVA, which supports our goal of EBITDA breakeven in 2021.
1Q20 Accomplishments and Trends
TherapeuticsMD Met or Beat Wallstreet Net Revenue Consensus for the Last 4 Quarters

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Actual Total Net Product Revenue</th>
<th>Wall Street Avg. Net Revenue Consensus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1 2020</td>
<td>$2.3M ANNOVERA</td>
<td>$12,250,657</td>
</tr>
<tr>
<td>Q4 2019</td>
<td></td>
<td>$15,901,680</td>
</tr>
<tr>
<td>Q3 2019</td>
<td></td>
<td>$8,213,341</td>
</tr>
<tr>
<td>Q2 2019</td>
<td></td>
<td>$6,078,865</td>
</tr>
</tbody>
</table>

ANNOVERA: Patient demand doubled in Q1 from Q4 and outpaced restocking into the channel in Q1.

* Wall Street Consensus Estimate per “estimize”
1Q 2020 Key Performance Metrics

**ANNOVERA® (segesterone acetate and ethinyl estradiol vaginal system)**

- 1Q20 net revenue: ~$2.3M
- 1Q20 total prescriptions (TRx) to patient\(^1\): 2,361
  - During February soft launch, Sales Reps promoted to 10 prescribers per territory and generated monthly TRx of ~970
  - Paused launch due to COVID-19 in early March
- 1Q20 Average (avg.) net revenue per unit\(^2\): ~$1,350
  - Adjudication rate: ~100%
- Expected avg. net revenue per unit during 2020: ~$1,200 - $1,400
  - ~77% of ANNOVERA patients are paying $0 copay
- # Healthcare professionals (HCPs) with TRx: ~1,140

**IMVEXXY® (estradiol vaginal inserts)**

- 1Q20 net revenue: ~$6.4M
- 1Q20 TRx to patient\(^1\): ~134,000
- 1Q20 net revenue per unit\(^2\): ~$48
  - Overall adjudication rate: ~44%
- # HCPs with TRx: 17,000
- Focus on fills allows for continued revenue growth
  - Avg. of 6 units per patient for those patients who started therapy over 12 months ago
  - Avg. of 4.2 units per patient in 2019

\(^1\) Source: Symphony

\(^2\) Average net revenue per unit calculated from sales to wholesalers and pharmacies
1Q20 Key Metrics: ANNOVERA

ANNOVERA Full Launch Month Interrupted by COVID-19

MONTHLY TRx

JAN: 671
FEB: 966
MAR: 724

COVID-19 Impact/
Paused Launch

Source: Symphony

Sales Reps to target all
prescribers per territory

Sales Reps promoted to 10
prescribers per territory
1Q 2020 Key Performance Metrics

BIJUVA® (estradiol and progesterone) capsules

- 1Q20 net revenue: ~$1.1M
- 1Q TRx to patients¹: ~26,000
- 1Q20 net revenue per unit²: ~$43
  - Overall adjudication rate: ~51%
- # HCPs with TRx: ~5,000

- Pausing BIJUVA promotional activities enhances funding for ANNOVERA and IMVEXXY post COVID-19

¹ Source: Symphony
² Average net revenue per unit calculated from sales to wholesalers and pharmacies
## Current Payer Coverage by Channel

<table>
<thead>
<tr>
<th></th>
<th>Coverage June 2020</th>
<th>Target Coverage Year-end 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ANNOVERA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Commercial</td>
<td>66% UR, 78%*</td>
<td>80%*</td>
</tr>
<tr>
<td>Medicaid</td>
<td>46%</td>
<td>60%</td>
</tr>
<tr>
<td>Department of Defense</td>
<td>On Formulary</td>
<td>On Formulary</td>
</tr>
<tr>
<td><strong>IMVEXXY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Commercial</td>
<td>72%</td>
<td>75%</td>
</tr>
<tr>
<td>Part D</td>
<td>37%+</td>
<td>70%</td>
</tr>
<tr>
<td><strong>BIJUVA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Commercial</td>
<td>66%</td>
<td>75%</td>
</tr>
</tbody>
</table>


*Anovera coverage includes unrestricted access and coverage with a step edit/prior authorization. +Includes PA to indication

Source: MMIT 6_1_20
Finance Update
### Financial Results: Comparison Q1 2020 to Q4 2019

<table>
<thead>
<tr>
<th></th>
<th>Q1 2020</th>
<th>Q4 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Balance Sheet</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash</td>
<td>$170,100,000</td>
<td>$160,830,000</td>
</tr>
<tr>
<td>Working Capital</td>
<td>$150,349,000</td>
<td>$153,354,000</td>
</tr>
<tr>
<td>Long-term Debt</td>
<td>$243,429,000</td>
<td>$194,635,000</td>
</tr>
<tr>
<td><strong>Income Statement</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Product Revenue, Net</td>
<td>$12,251,000</td>
<td>$15,902,000</td>
</tr>
<tr>
<td>Total Operating Expenses</td>
<td>$60,458,000</td>
<td>$57,415,000</td>
</tr>
<tr>
<td>Net Loss</td>
<td>($56,849,000)</td>
<td>($49,436,000)</td>
</tr>
<tr>
<td><strong>Statement of Cash Flow</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net Cash Used In Operating Activities</td>
<td>($39,111,000)</td>
<td>($50,797,000)</td>
</tr>
</tbody>
</table>
Corporate Wide Cost Reductions in Total Operating Expenses

- Expect 2Q20 total operating expenses to be $45.5M - $47.5M
  - Defer $10M in marketing spend primarily related to media
- Expect total operating expenses in 3Q20 and 4Q20 to be approximately $40M or less\(^1\)
- We believe these actions will continue to position us to become EBITDA break even in 2021

\(^1\)Spend of $40M per quarter in total operating expenses excluding non-cash items
Previous Sales Structure Supporting All Three Products

140 Sales Reps

30-40 Sales Reps

1
2
3

1
2

Annovera
1 mg/200 mcg per day

Imvexxy
4 mg - 10 mg

Bijuva
1 mg/100 mg

1
2
Current Sales Team and Distribution Channels

120-130 Sales Reps

- ANNOVERA is positioned as the lead product
- IMVEXXY is positioned as second detail
- BIJUVA promotional activities to be paused to create cost savings from the following:
  - Eliminating menopausal sales force
  - Reducing medical affairs support staff
  - Eliminating marketing spend
    - Advertising cost
    - Marketing agency costs
    - Social media cost
    - Brochures, marketing collateral, direct mail, etc.
  - Continued sampling

Distribution Channels

All trademarks are the property of their respective owners.
Advantages to Pausing BIJUVA

• A laser-focused sales force to drive market adoption of ANNOVERA and IMVEXXY

• Pausing BIJUVA promotional activities enhances funding for ANNOVERA and IMVEXXY post COVID-19

• Reduces operating expense and will not delay goal of EBITDA break even in 2021

• Using partners to increase patient access for ANNOVERA into Government, Public Health and Online markets to increase access and reduce cost

• BIJUVA opportunity and revenue build is delayed but not lost
Update to TPG Sixth Street Loan Covenants

- Due to the uncertainty created by COVID-19 and its impact on our business, TXMD has been in discussions with Sixth Street Partners regarding the revenue covenants in the loan document.
- We are working with Sixth Street to defer the scheduled start of the quarterly revenue covenant to reflect the impact of COVID-19.
- Sixth Street has expressed preliminary support and while there is currently no final agreement or obligation, they understand the importance of flexibility for our company at this time.
Product Overview and Plans to Drive Revenue Inflection Point
Our approach is strategic, highly focused and achievable:

- Now that we have patient, provider and net revenue data on all 3 of our products, we have developed a path to reduce overall expenses and reallocate our resources that maintains our goal of achieving EBITDA breakeven in 2021

- We believe we are positioned to capitalize on emerging market trends that have been accelerated by COVID-19 with our retail and online distribution channels

- In the short-term, we have adjusted our strategy to be primarily focused on ANNOVERA and IMVEXXY
# ANNOVERA: Well Positioned for Fast Uptake When Full Plans Deployed

## Contraception: Largest Women’s Health Category at $5B
- **~500,000** U.S. prescribers of contraception
- **~18M** women on prescription birth control annually
- **~28M** NRx in 2019

## Full Sales Force Plans and Consumer Advertising will Quickly Accelerate Ramp

### 1Q20 Efforts and Results
- **1,140** Prescribers
- **10** Providers per sales representative
- Paused launch of consumer campaign and live field promotion halted in March due to COVID-19

### 3Q20 Efforts
- **125-150** sales force targets per representative
- Large scale consumer campaign to launch in early Q3

## Broad Availability will Allow Growth Across Contraception Channels

### Retail/ Community Pharmacies
- BioIgnite

### Online Distribution Partners:
- Pill Club
- PlushCare
- SimpleHealth
- PillPack

### Public Health
- Universities, 340b including Title X (Planned Parenthood), Medicaid

### Military
- Currently being promoted to 92 military bases
ANNOVERA Compelling Now and Post COVID-19

- One year’s worth of contraceptive protection
- Good option for women who want a long-lasting option and do not want a procedure or cannot get access to a procedure

ANNOVERA is the only long-lasting contraceptive that is patient-controlled and procedure-free²

<table>
<thead>
<tr>
<th>Patient-controlled</th>
<th>IUDs</th>
<th>IMPLANTS</th>
<th>OTHER COMBINATION HORMONAL CONTRACEPTIVES</th>
</tr>
</thead>
<tbody>
<tr>
<td>✔</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procedure-free</td>
<td>✔</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✔</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long-lasting</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
</tbody>
</table>

- Covers women for a year even if their insurance situation changes
- ~77% of patients have $0 co-pay
- Available to be delivered to her door
IMVEXXY’s Unique Product Attributes

- Indicated for moderate to severe dyspareunia, a symptom of VVA, due to menopause
- Small, digitally inserted, softgel vaginal insert that dissolves completely
- **Easy to use without the need for an applicator**
- **Mess-free** administration
- **Use any-time of day**
- **Lowest approved doses** of estradiol 4 mcg and 10 mcg
- **Efficacy demonstrated as early as 2 weeks** (secondary endpoint) and maintained through week 12 in clinical studies
- **PK data** - **No increase in systemic hormone levels** beyond the normal postmenopausal range*
- **Dose packaging to optimize compliance and convenience**

*The clinical relevance of systemic absorption rates for vaginal estrogen therapies is not known.
IMVEXXY Continues to Gain Momentum

IMVEXXY is the fastest growing product in the VVA market and share gains vs. Premarin

- March 10.8% market share of TRx
- Support of high writer base and expansion of productive writers
  - New writers delivered 10% of 1Q NRx volume
- Consumer efforts are driving action
  - Intent to ask HCP about IMVEXXY continues to grow now at 66%
- Consumer media will expand to support continued share gain in back half of year
BIJUVA Targeted Focus Until 0.5/100 Launch is Funded

- Focus on current writer base through remainder of 2020
  - Non-personal promotion

- Focus on current Bio-ignite partners
  - Compounding pharmacists report that they would recommend BIJUVA for 1/3 of their estradiol and progesterone (E+P) patients

- Prepare for 0.5/100 launch in 2021 with internal resources, if approved
  - PDUFA date: November 16, 2020
2020 Post COVID-19 Outlook

- Currently regaining access to doctors’ offices in lock step as the states reopen
  – We expect office access to expand and accelerate during 2Q and normalize during 3Q
  – 2Q20 revenue will be impacted due to COVID-19

- We believe ANNOVERA and IMVEXXY are positioned to capitalize on current trends due to COVID-19
  – Expanded access through telehealth
  – Online and retail home delivery distribution

- Cash runway extended due to saving from pausing BIJUVA commercial activities and other cost-saving measures

- We expect to reactivate the growth drivers in early 3Q20
  – ANNOVERA full launch including launch of Consumer Campaign “Unapologetically ANNOVERA”
  – IMVEXXY acceleration of media and reengagement of in person sales efforts

- TPG Sixth Street Partners discussions ongoing

We believe we are well positioned to resume our growth trajectory in 3Q
Market Opportunity

<table>
<thead>
<tr>
<th>Average Net Revenue / Unit</th>
<th>1.0%</th>
<th>1.5%</th>
<th>2.0%</th>
<th>2.5%</th>
</tr>
</thead>
<tbody>
<tr>
<td>$1,000</td>
<td>$280M</td>
<td>$420M</td>
<td>$560M</td>
<td>$700M</td>
</tr>
<tr>
<td>$1,250</td>
<td>$350M</td>
<td>$525M</td>
<td>$700M</td>
<td>$875M</td>
</tr>
<tr>
<td>$1,500</td>
<td>$420M</td>
<td>$630M</td>
<td>$840M</td>
<td>$1.05B</td>
</tr>
<tr>
<td>$1,750</td>
<td>$490M</td>
<td>$735M</td>
<td>$980M</td>
<td>$1.2B</td>
</tr>
</tbody>
</table>

ANNOVERA Comparison to other Branded Products¹

- NuvaRing 2019 NRx of ~1.3M units from ~153K writers
- Lo Loestrin FE 2019 NRx of ~2.8M units from ~114K writers
- ANNOVERA NRx of ~400k units would @$1,250 a unit = ~$500M annual revenue

<table>
<thead>
<tr>
<th>Average Net Revenue / Unit</th>
<th>25%</th>
<th>35%</th>
<th>45%</th>
<th>55%</th>
</tr>
</thead>
<tbody>
<tr>
<td>$80</td>
<td>$184M</td>
<td>$257.6M</td>
<td>$331.2M</td>
<td>$404.8M</td>
</tr>
<tr>
<td>$100</td>
<td>$230M</td>
<td>$322M</td>
<td>$414M</td>
<td>$506M</td>
</tr>
</tbody>
</table>

¹ Symphony Health Metys Data
The Power of a Women’s Health Portfolio

CONTRACEPTION

PRENATAL CARE

CONTRACEPTION/FAMILY PLANNING - PERIMENOPAUSE

VASOMOTOR SYMPTOMS

DYSPAREUNIA (Vulvar & Vaginal Atrophy)

REPRODUCTIVE HEALTH

MENOPAUSE MANAGEMENT

TherapeuticsMD®
Appendix
On April 28, 2020, the USPTO issued the first Orange Book listable patent for ANNOVERA

- US Patent No 10,632,066 will expire February 2039
- On March 29, 2020, TherapeuticsMD filed FDA Form 3542 to have the ‘066 patent listed in the Orange Book
- The ‘066 patent claims elements of the ANNOVERA label, which a generic would need to copy as part of its Abbreviated New Drug Application (ANDA)

Currently on file with the USPTO are six additional utility patent applications for ANNOVERA and one design patent

- These applications cover different aspects of ANNOVERA and if issued would strengthen ANNOVERA’s exclusivity position
1Q20 Key Metrics: ANNOVERA

<table>
<thead>
<tr>
<th></th>
<th>1Q 2020</th>
<th>4Q 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Revenue</td>
<td>~$2.3M</td>
<td>~$5.8M</td>
</tr>
<tr>
<td>TRx to patients</td>
<td>2,361</td>
<td>1,095</td>
</tr>
<tr>
<td>Average Net Revenue / Unit</td>
<td>$1,350</td>
<td>$1,350</td>
</tr>
<tr>
<td># Prescribers w/ TRx</td>
<td>1,140</td>
<td>540</td>
</tr>
</tbody>
</table>

- Patient demand more than doubled 1Q20 over 4Q19 and outpaced unit sales into the channel
- Adjudication rate: ~100%
- ~77% of ANNOVERA patients are paying $0 copay

*Average net revenue per unit calculated from sales to wholesalers and pharmacies

ANNOVERA Full Launch Month
Interrupted by COVID-19

MONTHLY TRx

<table>
<thead>
<tr>
<th>JAN</th>
<th>FEB</th>
<th>MAR</th>
</tr>
</thead>
<tbody>
<tr>
<td>671</td>
<td>966</td>
<td>724</td>
</tr>
</tbody>
</table>

Source: Symphony

Reps promoted to 10 Prescribers per territory
Launched to all Prescribers
# 1Q Key Metrics: IMVEXXY

<table>
<thead>
<tr>
<th></th>
<th>1Q 2020</th>
<th>4Q 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Revenue</td>
<td>~$6.4M</td>
<td>~$6.35M</td>
</tr>
<tr>
<td>TRx to patients</td>
<td>134,000</td>
<td>123,300</td>
</tr>
<tr>
<td>Average Net Revenue / Unit</td>
<td>$48</td>
<td>$51</td>
</tr>
<tr>
<td># Prescribers w/ TRx</td>
<td>17,000</td>
<td>16,500</td>
</tr>
</tbody>
</table>

- Patient demand increased Q over Q
- Not as heavily impacted by COVID-19
- Established base of business across writers and patients
- Overall adjudication rate (Q1): ~44%

* Calculated Net Revenue per Unit = GAAP Net Revenue divided by number of prescriptions filled by patients in period

Source: Symphony
1Q Key Metrics: BIJUVA

<table>
<thead>
<tr>
<th></th>
<th>1Q 2020</th>
<th>4Q 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Revenue</td>
<td>~$1.1M</td>
<td>~$1.2M</td>
</tr>
<tr>
<td>TRx to patients</td>
<td>~26,000</td>
<td>~21,600</td>
</tr>
<tr>
<td>Average Net Revenue / Unit</td>
<td>$43</td>
<td>$56</td>
</tr>
<tr>
<td># Prescribers w/ TRx</td>
<td>5,000</td>
<td>5,500</td>
</tr>
</tbody>
</table>

- Overall adjudication rate Q1: ~51%
- Continued growth in patient demand quarter over quarter

BIJUVA TRx Continued to Ramp Throughout the Quarter

* Calculated Net Revenue per Unit = GAAP Net Revenue divided by number of prescriptions filled by patients in period
Payor Progress: ANNOVERA

- Surpassed IMVEXXY and BIJUVA progress in January 2020 with payor coverage, adjudication, and net revenue per unit
  - Public Health Expansion fast progress with our partners Afaxys and WSI
    - Added to formulary for Department of Defense and being sold to 92 military bases
    - Available for Title X entities (e.g. Planned Parenthood)
    - Expect universities to adopt and prescribe ANNOVERA during Fall semester
- Medicaid market is 15% of contraceptive volume
  - 37 states now unrestricted in Medicaid* with average copays of $5 or less
- ~78% coverage and ~77% patients paying $0 copay even without the 19\textsuperscript{th} category
  - Positive engagement with FDA continues

* Fee for Service Medicaid
Payor Progress: Menopausal Products

- IMVEXXY Commercial access remains solid at 72% unrestricted
  - Four of top eight Medicare Part D payors cover IMVEXXY
  - COVID-19 has slowed down the payor review process for Part D
  - Since January 1st, IMVEXXY has added 20 states with unrestricted Medicaid* access with average copays of $5 or less

- BIJUVA Commercial access remains at 66% unrestricted and discussions are ongoing
  - We have achieved access with 8 of the top 10 commercial payors
  - Since January 1st, BIJUVA has added 21 states with unrestricted Medicaid* access with average copays of $5 or less

* Fee for Service Medicaid